Neuroblastoma is a common solid tumour of childhood and advanced disease carries a poor prognosis despite intensive multi-modality therapy. Hypoxia is a common feature of solid tumours due to poorly organised tumour-induced neovasculature. Hypoxia is associated with advanced stage and poor outcome in a range of tumour types, and leads to resistance to clinically relevant cytotoxic agents in neuroblastoma and other paediatric tumours in vitro. Resistance to apoptosis is a common feature of tumour cells, and leads to pleiotropic drug resistance, mediated by Bcl-2 family proteins. ABT-737 is a novel small molecule inhibitor of Bcl-2 and Bcl-x L that is able to induce apoptosis in a range of tumour types. Neuroblastoma cell lines are relatively resistant to ABT-737-induced apoptosis in normoxia, but in contrast to the situation with conventional cytotoxic agents, are more sensitive in hypoxia. This sensitisation is due to an increase in ABT-737-induced apoptosis and is variably dependent upon the presence of functional HIF-1α. In contrast to the situation in colon carcinoma and non small cell lung cancer cells hypoxia does not result in down-regulation of the known ABT-737 resistance factor, Mcl-1, nor any other Bcl-2 family proteins. ABT-737 sensitises neuroblastoma cells to clinically relevant cytotoxic agents under normal levels of oxygen, and importantly this sensitisation is maintained under hypoxia, when neuroblastoma cells are resistant to these agents. Thus rational combinations of ABT-737 and conventional cytotoxics offer a novel approach to overcoming hypoxia-induced drug resistance in neuroblastoma.
Introduction
Neuroblastoma is the commonest extracranial solid tumour of childhood.
Significant numbers of patients have widely disseminated disease and have poor survival despite intensive multi-agent induction chemotherapy, myeloablative therapy, radiotherapy, surgery and 13-cis retinoic acid (1) , and for patients with an inadequate response to induction chemotherapy the outcome is very poor (2) .
Hypoxia, a reduction in the level of tissue oxygen, is a common feature of solid tumours because of reduced blood flow in the tumour-induced neovasculature (3) . Hypoxia is associated with decreased survival and advanced stage in several types of adult tumour, including squamous cell carcinomas of the head and neck, and carcinoma of the cervix (4). Hypoxia has long been known to decrease the effectiveness of radiotherapy, and more recent studies have shown that cytotoxic agents are also less effective under conditions of low oxygen (5, 6) . In neuroblastoma cells hypoxia reduces etoposide, and vincristine-induced apoptosis (7) and leads to resistance to cisplatin (8) . Similar effects of hypoxia are seen in the common paediatric tumours rhabdomyosarcoma and Ewing's sarcoma (9) . The principle modulator of tumour cell response to hypoxia is the transcription factor hypoxia-inducible factor 1 (HIF-1) (10) . HIF-1 is a heterodimer of HIF-1α and HIF-1β; HIF-1β is constitutively expressed, but HIF-1α levels are kept low through proteasomal degradation in normoxia (11, 12) . Under hypoxic conditions HIF-1α is no longer targeted for degradation and is able to dimerise with HIF-1β and transactivate target genes (13) . HIF-1α is stabilised in neuroblastoma cell lines in hypoxia, and HIF-1 target genes including VEGF and tyrosine hydroxylase are upregulated, both in vitro and as xenografts (14) . Multiple angiogenic factors, including VEGF, have been shown to be expressed in neuroblastomas in vivo, and higher level expression correlates with advanced disease and poor outcome (15) .
Failure of apoptosis is considered a hallmark of cancer (16) . Commitment to apoptosis via the mitochondrial pathway is controlled by interactions between anti-and pro-apoptotic Bcl-2 family members which share homology via their BH-3 domains (17) . The multi-domain pro-apoptotic Bcl-2 family proteins Bax and Bak are essential for mitochondrial apoptosis and their activity is controlled by the BH-3 only pro-apoptotic Bcl-2 family proteins. Two models have been suggested for this activation of Bax and Bak. In the 'direct model', BH-3-only proteins directly activate Bax and Bak, whilst in the 'indirect model' BH-3 only proteins bind to anti-apoptotic family members and prevent them from binding to and inhibiting Bak and Bax (18) . Activation of Bax and Bak results in release of apoptogens from the mitochondrial inter membrane space and activation of an amplifying cascade of caspase-mediated proteolysis (19) .
ABT-737 is a novel small molecule that mimics the BH-3 domain of Bad and binds with nanomolar affinity to the hydrophobic pocket of Bcl-2, Bcl-x L and Bcl-w, disrupting their interactions with death-promoting Bcl-2 family members, and releasing these to activate Bax and Bak and engage apoptosis (20) (see Supplemental Figure 1 for the chemical structure of ABT-737 and other drugs used in this study). ABT-737 sensitizes a number of adult cancer cell types to cytotoxic agents (21) , and has activity against acute myeloid leukaemia, and small cell lung cancer (SCLC), as a single agent in pre-clinical Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. models (20, 22, 23) . ABT-737 binds poorly to Mcl-1 and thus tumour cell expression of Mcl-1 is associated with resistance to ABT-737 (24, 25) . ABT-263, an orally bio-available counterpart with similar biological activity, has been evaluated against the paediatric testing panel and has single agent activity against acute lymphoblastic leukaemia (26). ABT-263 is now in clinical trial against adult tumours (27) . In this study we have evaluated the efficacy of ABT-737 against neuroblastoma cell lines in hypoxia, both as a single agent and in combination with clinically relevant cytotoxic agents.
Methods

Cell Culture
Both MYCN amplified and MYCN non-amplified neuroblastoma cell lines were used. In addition phenotypically distinct S and N-type subclones of SK-N-SH and LA-N-1 were studied. SH-EP1, SH-SY5Y, LA1-55n and LA1-5s were the kind gift of Dr. Robert Ross (Fordham University, Bronx, NY), NGP cells were a kind gift from Dr Deborah Tweddle (University of Newcastle-upon-Tyne), IMR-32 cells were purchased from ATCC-LGC. All cell lines were authenticated by CRUK in July 2010 using STR profiling. All cell lines were maintained in DMEM-F12 with 10% FCS (Gibco, Invitrogen, Paisley, United Kingdom). SH-EP1 clones stably expressing mouse Bcl-2 or shRNA against
Mcl-1 were a kind gift from Professor Simone Fulda (Institut für Experimentelle Tumorforschung in der Pädiatrie, Goethe-Universität, Frankfurt am Main, Germany). For hypoxia experiments, cells were cultured and treated in a sealed modular incubator (InVivo2 Hypoxia workstation 400) flushed with 1% O2, 5% CO2, and 94% N2 (hereafter referred to as hypoxia).
Drug treatment
10mM stock of ABT-737 (Abbott Laboratories, Illinois, USA) was dissolved in DMSO and initial dose response curves for all cell lines were generated using DMSO and a less potent enantiomer (20) as control. The sulforhodamine B (SRB) assay was used to determine total protein reflecting cell number after treatment. Cells were plated in exponential growth phase in 96-well plates and treated for 24-72 hours with varying concentrations of ABT-737 or conventional cytotoxics. Cells were fixed and stained according to standard SRB protocol (28) , and absorbance was measured using a microplate reader (Labsystems Multiskan EX, Thermo Scientific) at 540nm.
siRNA treatment
HIF-1α knock-down was achieved using siGENOME SMART pool from Dharmacon Thermo Scientific, control oligos were non-target pool from the same supplier. Cells were treated in 96 or in 6 wells plates as per manufacturer instructions.
Western Blotting
Cells were washed with PBS and lysed into either cell lysis buffer (Cell Signaling) supplemented with Protease Inhibitor Cocktail and Phosphatase Inhibitor Cocktail I and II (Sigma), or directly into 2x Laemmli sample buffer.
Loading was normalised by cell number or by protein concentration which was determined by bicinchoninic acid assay (Thermo Scientific) following the manufacturer's instructions, both methods gave similar results. Samples were run on appropriate percentage polyacrylamide gels, and transferred to 
Drug combination assays
Data from the SRB assay, performed in triplicate, were used to calculate combination index (CI) with CalcuSyn software (Biosoft, Cambridge, UK) (29) .
This method is based on the multiple drug-effect equation of Chou-Talalay derived from enzyme kinetic models (30) . Based on this approach, combination index values <0.9 are considered synergistic, >1.1 are antagonistic, and values 0.9 to 1.1 are nearly additive. The ratios of ABT-737 and cytotoxic drugs were fixed using IC50 values obtained by the SRB assay.
Cells were co-treated for 24-72 hours using ABT-737 and the cytotoxic drugs doxorubicin, cisplatin, etoposide, and vincristine. Six drug concentrations were used covering the concentration-effect. Linear correlation coefficients (r) were generated for each concentration response curve to determine the applicability of the data to the method of analysis. In all experiments, r was >0.9.
Statistical analysis
Two-way ANOVA followed by the Bonferroni test was used to establish whether significant differences existed between normoxic and hypoxic conditions over a range of doses. Student's t test calculations were performed on single dose response data and IC50 calculations. 
Sensitisation to ABT-737 in hypoxia is due to increased apoptosis
The SRB assay is a measure of protein, and as such will give information only about cell number. To address the mode of hypoxic sensitisation to ABT-737, To test whether differences in expression of the ABT-737 target Bcl-2 could account for differences in sensitivity to ABT-737 the responses of SH-EP1 cells stably over-expressing mouse Bcl-2 were investigated. ABT-737 is able to bind to and inhibit mouse Bcl-2 with a similar level of efficacy to human Bcl-controls (SHEP-pMSCV), and this is not due to any difference in their levels of human Bcl-2 ( Figure 3B ). However this clear increase in level of Bcl-2 protein has no effect upon the response of SH-EP1 cells to ABT-737 in normoxia, in which no difference can be seen between wild type SH-EP1 cells, SH-EP1 cells expressing mouse Bcl-2 and SH-EP1 cells containing vector alone in SRB assay ( Figure 3C ). In addition overexpression of Bcl-2 had no effect upon the induction of apoptosis by ABT-737 in SH-EP1 cells in normoxia as measured by flow cytometry for annexin V, or on the sensitisation of SH-EP1 cells to ABT-737-induced apoptosis in hypoxia ( Figure 3D ). Thus levels of Bcl-2 do not modulate sensitivity to ABT-737 in normoxia in these neuroblastoma cell lines.
Sensitisation of neuroblastoma cells to ABT-737 in hypoxia is variably dependent on HIF-1α
HIF-1 is the central regulator of cellular response to hypoxia, and we and others have previously shown that resistance to cytotoxic agents in hypoxia in neuroblastoma cell lines is dependent upon HIF-1α (7, 8) Synergy between ABT-737 and conventional cytotoxic agents in normoxia has been reported in a range of adult tumour types (21) , and ABT-737 is able to reverse 13-cis-retinoic acid-induced resistance to cytotoxic agents in neuroblastoma cell lines (38) . Our previous work in SCLC and CRC had shown that this synergy was maintained, and occasionally enhanced, in hypoxia (31). In the current study this enhancement of the interaction between ABT-737 and conventional clinically relevant cytotoxic agent was more pronounced. Thus although a degree of synergy between ABT-737 and cytotoxic agents was seen across all 4 neuroblastoma cell lines in normoxia, it was almost invariably more marked in hypoxia (Table 1 
neuroblastoma cells in hypoxia, ABT-737 is also better able to sensitise neuroblastoma cell lines to conventional cytotoxic agents in hypoxia.
In conclusion this study shows that ABT-737 is more effective against neuroblastoma cell lines under hypoxia than normoxia, and importantly is better able to synergise with conventional cytotoxic agents under hypoxia, when neuroblastoma cells are more resistant to these agents. This data have potential significance for the future use of Bcl-2 family targeting drugs against neuroblastoma suggesting that combination with conventional cytotoxics may offer a possible strategy for improving the survival of children with this poor prognosis disease. However further work will be needed to investigate these combinations in animal models. 
